Streetbeat News

NBSE

NeuBase Therapeutics Inc

https://www.neubasetherapeutics.com/

CEO

Dietrich Stephan

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

neubase has developed a modular antisense technology platform with the capability to address any rare genetic disease caused by mutant proteins with a single, cohesive approach. neubase's platform improves upon gene silencing therapies by combining the advantages of synthetic approaches with the precision of antisense technologies. neubase plans to use its unparalleled antisense platform to address both repeat expansion disorders, with an initial focus on huntington's disease and myotonic dystrophy, and dominant genetic disorders.

Open

0.38

Mkt cap

1.4M

Volume

90K

High

0.39

P/E Ratio

-0.02

52-wk high

4.44

Low

0.36

Div yield

N/A

52-wk low

0.36

In Monday's pre-market session, several healthcare stocks showed significant movement. Monogram Orthopaedics, Allarity Therapeutics, VYNE Therapeutics, Allogene Therapeutics, Sunshine Biopharma, and Addex Therapeutics were among the gainers, with increases ranging from 12.4% to 19.1%. Conversely, GlycoMimetics, Acutus Medical, EyePoint Pharmaceuticals, NeuBase Therapeutics, Ocular Therapeutix, and Predictive Oncology experienced declines between 13.82% and 78.7%.

Portfolio Pulse from Benzinga Insights

May 06, 2024 | 12:06 pm

In Friday's after-market session, several healthcare stocks experienced significant movements. NeuBase Therapeutics, Aptevo Therapeutics, Galera Therapeutics, Alzamend Neuro, Asensus Surgical, and cbdMD were among the gainers, with increases ranging from 5.24% to 11.1%. Conversely, Acutus Medical, HeartBeam, Mustang Bio, Palisade Bio, Trevena, and Monopar Therapeutics saw declines between 5.0% and 16.4%.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 8:31 pm

NeuBase Therapeutics anticipates that trading of its common stock will be suspended at the start of business on May 13, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 8:03 pm

NeuBase Therapeutics Inc was notified by Nasdaq on May 2 that it has not regained compliance with the minimum bid price requirement, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 8:02 pm

In Friday's after-market session, several healthcare stocks showed notable movements. Qilian Intl Hldg Gr (QLI) led the gainers with a 50.4% increase, while PaxMedica (PXMD) experienced the largest decline among the losers, dropping 8%. Other notable movers included Allarity Therapeutics (ALLR) and Cormedix (CRMD) with significant gains, and OncoCyte (OCX) which declined following its Q4 earnings release.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 8:31 pm

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) received a notice from Nasdaq on April 4, 2024, for not complying with the continued listing requirements due to its failure to timely file its Annual Report for the fiscal year ended December 31, 2023. The company has until June 3, 2024, to submit a compliance plan, with a potential extension until September 30, 2024, to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 8:09 pm

NeuBase Therapeutics Inc (NASDAQ:NBSE) shares plummeted by 53% to $0.47 after announcing a Special Meeting of Stockholders to vote on the company's proposed liquidation and dissolution. The Board of Directors recommends approval of these proposals. The meeting is set for May 13, online, with registration required by May 12. The company does not pay dividends or have recent buyback programs. NBSE's 52-week trading range is between $0.59 and $5.40.

Portfolio Pulse from Henry Khederian

March 26, 2024 | 6:43 pm

Westport Fuel Systems Inc. (NASDAQ:WPRT) shares fell by approximately 10% after reporting a Q4 loss wider than expected. Other stocks experienced significant movements, with notable gainers including Stoke Therapeutics, Inc. (NASDAQ:STOK) and losers like Quhuo Limited (NASDAQ:QH). The movements were attributed to various factors including financial results, clinical trial data, and strategic agreements.

Portfolio Pulse from Avi Kapoor

March 26, 2024 | 5:45 pm

Healthcare stocks experienced significant movements in Tuesday's intraday session. Stoke Therapeutics (STOK) led the gainers with a 71.8% increase following their Q4 earnings report. Other notable gainers include Mesoblast (MESO), OpGen (OPGN), Alpha Teknova (TKNO), Nuvation Bio (NUVB), and Journey Medical (DERM). On the losing side, NeuBase Therapeutics (NBSE) saw the largest decline of 51.8%. Other decliners were Prenetics Global (PRE), Equillium (EQ), SCWorx (WORX), Monte Rosa Therapeutics (GLUE), and Biodexa Pharmaceuticals (BDRX).

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 5:31 pm

U.S. stocks traded higher with the Nasdaq gaining over 50 points. Consumer discretionary shares rose by 0.7%, while energy shares fell by 0.2%. U.S. durable goods orders increased by 1.4% in February. Stocks like Stoke Therapeutics, C3is Inc., and OpGen saw significant gains, whereas NeuBase Therapeutics, Quhuo Limited, and AppTech Payments Corp experienced sharp declines.

Portfolio Pulse from Avi Kapoor

March 26, 2024 | 2:09 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.